Forte Biosciences, Inc.
FBRX
$6.32
-$0.34-5.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 14.74% | 32.92% | -68.61% | -26.36% | 41.01% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 11.11% | 50.00% | 100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.38% | 0.38% | -0.25% | 1.40% | 20.49% |
| Change in Net Operating Assets | -517.97% | -109.55% | 10,587.27% | 98.59% | -1,721.25% |
| Cash from Operations | -23.07% | -37.01% | 10.96% | 25.67% | 0.98% |
| Capital Expenditure | -- | -- | 100.00% | 64.71% | 76.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -99.99% |
| Cash from Investing | -- | -- | 100.00% | 62.50% | -100.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 883,233.33% | -- | -100.00% | -96.17% | -99.16% |
| Repurchase of Common Stock | 71.43% | 30.00% | 37.50% | -33.33% | 50.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -112,000.00% | -- | -- | -- | -- |
| Cash from Financing | 2,593,950.00% | 80.00% | -25.00% | 89.33% | -100.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 172.29% | -36.81% | 11.00% | 26.26% | -135.19% |